| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.015 | 0.6 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.6 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | ABT-888 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | necrostatin-7 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |